On-treatment and projected sustained viral responses with boceprevir-based triple therapy in previous treatment-failure HCV patients with advanced fibrosis or cirrhosis. Interim analysis of the Hungarian named patient program cohort

Pal Ribiczey, Zsofia Ozsvar,Zsofia Muller, E Makkai,Mihaly Makara, V Jancsik,G Horvath,A Haragh, K Csefko,M Abonyi,Bela Hunyady, B Sipos,O Szabo, Ferenc Szalay,L Szentgyorgyi,Eszter Ujhelyi,M Varga,G Weisz

Zeitschrift Fur Gastroenterologie（2013）

引用 0|浏览21

暂无评分

摘要

Background and Aims: Efficacy and safety of boceprevir+peginterferon/ribavirin (B+PR) therapy in pervious treatment failure HCV genotype 1 pts with advanced liver fibrosis (F3) or cirrhosis (F4) have been analyzed, with special attention to previous null-responder cirrhotics.

查看译文

关键词

sustained viral responses,triple therapy,cirrhosis,on-treatment,boceprevir-based,treatment-failure

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要